Edgewise Therapeutics (EWTX) Free Cash Flow (2020 - 2026)

Edgewise Therapeutics has disclosed Free Cash Flow across 7 years of filings, most recently posting -$42.6 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$42.6 million, down 12.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$148.7 million (down 25.8% YoY), and the FY2025 annual result was -$144.1 million, down 32.09% from the prior year.
• Free Cash Flow came in at -$42.6 million for Q1 2026 at Edgewise Therapeutics, down from -$38.8 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$11.8 million in Q4 2022 to a low of -$42.6 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$27.0 million (2023), against an average of -$26.4 million.
• Across the five-year window, Free Cash Flow plunged 129.03% in 2023 and rose 0.72% in 2024, its largest moves.
• Edgewise Therapeutics' Free Cash Flow stood at -$11.8 million in 2022, then slumped by 129.03% to -$27.0 million in 2023, then advanced by 0.72% to -$26.8 million in 2024, then tumbled by 44.8% to -$38.8 million in 2025, then retreated by 9.75% to -$42.6 million in 2026.
• The last three Free Cash Flow figures came in at -$42.6 million (Q1 2026), -$38.8 million (Q4 2025), and -$34.7 million (Q3 2025), per Business Quant data.